Investor Presentation
76
Investor presentation First six months of 2022
Building upon a 40-year legacy to capture the Rare disease
strategic opportunity
A strategy anchored in Rare blood and endocrine disorders
Three strategic horizons towards 2030
Hemato-renal
Haemoglobinopathies
Haemolytic anaemia
Iron disorders
Haemophilia
HV
Lysosomal storage disorders
Today
Rare pituitary & adrenal
disorders
Bone/calcium
imbalances
Short-term
Growth disorders
Maximise current
portfolio
Growth hormone
disorders
RBD RED
Rare blood disorders Rare endocrine disorders
esperoct norditropin®
turoctocog alfa pegol
refixia®
nonacog beta pegol
(somatropin) injection
NovoSevenⓇRT
Coagulation Factor Vila
(Recombinant)
Novo NordiskⓇ
Medium-term
Succeed with next-
generation launches
Long-term
Expand from core
New disease areas
via accelerated
internal and external
innovation
SOGROYA
somapacitan
Concizumab
& Mim8
NedosiranView entire presentation